Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

82.91USD
16 Oct 2018
Change (% chg)

$2.90 (+3.62%)
Prev Close
$80.01
Open
$80.59
Day's High
$82.95
Day's Low
$80.05
Volume
236,714
Avg. Vol
294,645
52-wk High
$153.80
52-wk Low
$78.93

Select another date:

Thu, Sep 27 2018

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

UPDATE 4-Early approval of Alnylam's gene-silencing drug in question

* Co still plans to discuss potential early approval with FDA

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics

* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran

* ALNYLAM ACHIEVES ALIGNMENT WITH FDA ON ACCELERATED DEVELOPMENT PATH FOR LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis

* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:

Select another date: